Neuronetics, Inc. Stock price

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-02-23 pm EST 5-day change 1st Jan Change
3.29 USD +0.30% Intraday chart for Neuronetics, Inc. +6.13% +13.45%
Sales 2023 * 71.05M Sales 2024 * 78.64M Capitalization 95.19M
Net income 2023 * -32M Net income 2024 * -28M EV / Sales 2023 * 1.34 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 1.21 x
P/E ratio 2023 *
-2.91 x
P/E ratio 2024 *
-3.45 x
Employees 211
Yield 2023 *
-
Yield 2024 *
-
Free-Float 93.97%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.30%
1 week+6.13%
Current month-3.24%
1 month-1.79%
3 months+145.52%
6 months+105.62%
Current year+13.45%
More quotes
1 week
2.82
Extreme 2.82
3.34
1 month
2.82
Extreme 2.82
3.92
Current year
2.41
Extreme 2.41
3.92
1 year
1.03
Extreme 1.03
5.81
3 years
1.03
Extreme 1.03
17.92
5 years
1.03
Extreme 1.03
22.43
10 years
1.03
Extreme 1.03
39.39
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 20-07-13
Director of Finance/CFO 60 -
Chief Tech/Sci/R&D Officer - 21-02-28
Members of the board TitleAgeSince
Chairman 69 21-03-31
Director/Board Member 63 19-10-31
Director/Board Member 67 05-04-30
More insiders
Date Price Change Volume
24-02-23 3.29 +0.30% 96,776
24-02-22 3.28 +2.66% 75,325
24-02-21 3.195 +5.45% 189,460
24-02-20 3.03 -2.26% 116,393
24-02-16 3.1 -1.74% 211,032

Delayed Quote Nasdaq, February 23, 2024 at 04:00 pm EST

More quotes
Neuronetics, Inc. is a commercial stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.29 USD
Average target price
6.667 USD
Spread / Average Target
+102.63%
Consensus
  1. Stock
  2. Equities
  3. Stock Neuronetics, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer